After completing the independent medical educational activity, learners will be able to:
- Improve learners knowledge and understanding about latest evidence-based findings about TKIs efficacy in CML patients with failed prior lines of therapies.
- Based on the knowledge learned from the activity, learners will be able to develop effective strategies regarding TKIs usage in CML patients with failed prior lines of therapies.
Ehab Atallah
*Section Head, hematological malignancies, Medical College of Wisconsin, Milwaukee, WI, USA
Kendra Sweet
*Department of Malignant Hematology H. Lee Moffitt Cancer Center Tampa, FL, USA.
Giuseppe Saglio
*Division of Internal Medicine and Haematology, University of Turin, Turin, Italy.
Panelists: Ehab Atallah, Giuseppe Saglio and Kendra Sweet
*Section Head, hematological malignancies, Medical College of Wisconsin, Milwaukee, WI, USA, *Division of Internal Medicine and Haematology, University of Turin, Turin, Italy & *Department of Malignant Hematology H. Lee Moffitt Cancer Center Tampa, FL, USA
Certificate of attendance: The certificates will be given to those attendees who will complete pre & post symposium evaluation quiz.
Conflict of interests: No known conflict of interests
Acknowledgment: This symposium is supported by an educational grant from Pfizer.